Eligibility Module

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module

Ignite Creation Date: 2025-12-24 @ 11:19 PM
Ignite Modification Date: 2025-12-24 @ 11:19 PM
NCT ID: NCT00122356
Eligibility Criteria: Inclusion Criteria: * Postmenopausal * Adequately diagnosed and treated Stage I-IIIa early breast cancer * Oestrogen receptor and/or progesterone receptor positive breast cancer * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2 * Hormone replacement therapy (HRT) must be discontinued at least 2 weeks prior to registration * Any prior tamoxifen taken for a total of 8 weeks or less * Any prior anastrozole taken for a total of 4 weeks or less * Anastrozole is clinically indicated to be the best adjuvant strategy * Signed written informed consent Exclusion Criteria: * Clinical or radiological evidence of distant spread of disease * Prior treatment with bisphosphonates within the past 12 months * Prior treatment with continuous systemic corticosteroids within the past 12 months * Prior use of parathyroid hormone for more than 1 week * Prior use of systemic sodium fluoride for \> 3 months during the past 2 years * Currently treated with any drugs known to affect the skeleton * Abnormal renal function (serum creatinine greater than or equal to 265.2 mmol/L) * History of diseases with influence on bone metabolism. Patients with lactose intolerance are also excluded * Delayed oesophageal emptying such as stricture or achalasia * Hypersensitivity to alendronate or anastrozole * Previous or concomitant malignancy within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix * AST/SGOT and/or ALT/SGPT \> 3 x ULN in combination with other laboratory and clinical abnormalities indicating liver insufficiency * Fracture due to minimal trauma, demonstrated radiologically
Healthy Volunteers: False
Sex: FEMALE
Study: NCT00122356
Study Brief:
Protocol Section: NCT00122356